Infections

Skin and Connective Tissue Diseases

All Conditions

Musculoskeletal Diseases

Symptoms and General Pathology

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Warts

Foot Diseases

Communicable Diseases

Papillomavirus Infections

Virus Diseases

DNA Virus Infections

Skin Diseases

Skin Diseases, Viral

Tumor Virus Infections

Skin Diseases, Infectious

Nowarta110 contains fig extract as the main drug substance, and colloidal silver is used as a medium for penetration of fig extract into the wart lesion. Liquid for topical administration.

Nowarta110

Matching placebo liquid for topic administration.

Placebo

Dr. Iraj E Kiani

To evaluate drug safety and efficacy in patients treated with Nowarta110 and to determine therapeutic activity against Plantar Warts

* Clinical Tolerance
* Clinical Recovery
* Evaluate Safety

Plantar Warts occur on the soles (plantar surface of feet) and can be severely debilitating for patients even for normal walking. The severity and magnitude of the warts can vary, but they are the cause of much pain and discomfort for all age groups. Nowarta 110 has been evaluated for the therapy of plantar warts caused by the HPV virus, (HPV infection). Clinical experience in a totals of 124 patients receiving Nowarta 110 for 5 weeks treatment in multiple clinics overseas has demonstrated the potential of Nowarta110 with absolutely no side effect.

A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts

A Phase I/II, Two- Staged Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Nowarta110 in Patients With Plantar Warts and Clinical Recovery Successfully Completed

Lesion (plantar wart) size measured in millimeters. Measurement of the longest dimension was recorded. Observed data

Percent of participants with lesion measurement either equal to 0 or greater than 0

Nowarta Biopharma Inc

Total

Age, Continuous

Sex: Female, Male

Race (NIH/OMB)

Peggy Hagerty

Baseline

Week 1

Week 2

Week 3

Week 4

Week 5

Week 6

TREATMENT

Lesion Assessment

Lesion Measurement = 0

Lesion Measurment > 0

Incidence of Zero Lesion Measurement

Nowarta110 3 drops administered topically

Norwarta110 3 Drops

Nowarta110 6 drops administered topically

Nowarta110 6 Drops

Nowarta110 10 drops administered topically

Nowarta110 10 Drops

Overall Study

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts	NCT02338336	Plantar Warts	Nowarta110 Placebo	18 Years -	Nowarta Biopharma Inc
A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts	NCT02338336	Plantar Warts	Nowarta110 Placebo	18 Years -	Nowarta Biopharma Inc

Spots Global Cancer Trial Database for nowarta110

Every month we try and update this database with for nowarta110 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for nowarta110

Every month we try and update this database with for nowarta110 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for nowarta110 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.